(AMRX) Amneal Pharmaceuticals - Ratings and Ratios
Generics, Injectables, Biosimilars, Specialty, CNS
Dividends
Currently no dividends paid| Risk via 10d forecast | |
|---|---|
| Volatility | 32.4% |
| Value at Risk 5%th | 48.6% |
| Relative Tail Risk | -8.80% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 1.26 |
| Alpha | 36.73 |
| CAGR/Max DD | 1.46 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.527 |
| Beta | 0.864 |
| Beta Downside | 0.887 |
| Drawdowns 3y | |
|---|---|
| Max DD | 52.96% |
| Mean DD | 10.10% |
| Median DD | 7.25% |
Description: AMRX Amneal Pharmaceuticals November 08, 2025
Amneal Pharmaceuticals, Inc. (NYSE: AMRX) is a U.S.–based biopharma that develops, manufactures, markets, and distributes a broad portfolio of generic, injectable, biosimilar, and specialty branded medicines worldwide. The firm operates through three business segments: Affordable Medicines (generic oral solids, injectables, inhalation, biosimilars, etc.), Specialty (neurology and endocrine products such as Rytary for Parkinson’s disease and Unithroid for hypothyroidism), and AvKARE (government-focused distribution of pharmaceuticals and medical supplies).
In fiscal 2023 the company reported approximately $2.1 billion in revenue, with the Affordable Medicines segment contributing roughly 65 % of total sales. Its pipeline includes more than 30 late-stage generic and biosimilar candidates, positioning Amneal to capture a share of the global generics market, which is projected to grow at a 5-6 % CAGR through 2028 driven by cost-containment pressures in payer systems.
Key sector drivers that could affect AMRX’s outlook include (1) the aging U.S. population, which expands demand for chronic-disease therapies such as Parkinson’s and endocrine treatments; (2) ongoing regulatory incentives for biosimilar adoption that may boost margins on high-value injectable products; and (3) pricing volatility in the generic market, where competitive tendering and the “price-cutting spiral” can erode profitability if volume growth does not offset lower unit prices.
If you want a data-rich, quantitative deep-dive on Amneal’s valuation metrics and scenario analysis, the ValueRay platform offers tools that can help you model those drivers more precisely.
Piotroski VR‑10 (Strict, 0-10) 3.5
| Net Income (5.90m TTM) > 0 and > 6% of Revenue (6% = 176.1m TTM) |
| FCFTA 0.07 (>2.0%) and ΔFCFTA 0.16pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 33.27% (prev 15.60%; Δ 17.67pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.09 (>3.0%) and CFO 327.8m > Net Income 5.90m (YES >=105%, WARN >=100%) |
| Net Debt (2.48b) to EBITDA (555.6m) ratio: 4.47 <= 3.0 (WARN <= 3.5) |
| Current Ratio 2.13 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (324.8m) change vs 12m ago 4.88% (target <= -2.0% for YES) |
| Gross Margin 36.76% (prev 36.68%; Δ 0.09pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 83.13% (prev 77.45%; Δ 5.69pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 1.28 (EBITDA TTM 555.6m / Interest Expense TTM 246.5m) >= 6 (WARN >= 3) |
Altman Z'' 1.67
| (A) 0.27 = (Total Current Assets 1.84b - Total Current Liabilities 862.1m) / Total Assets 3.60b |
| (B) -0.16 = Retained Earnings (Balance) -570.1m / Total Assets 3.60b |
| (C) 0.09 = EBIT TTM 315.2m / Avg Total Assets 3.53b |
| (D) -0.18 = Book Value of Equity -672.8m / Total Liabilities 3.71b |
| Total Rating: 1.67 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 61.68
| 1. Piotroski 3.50pt |
| 2. FCF Yield 3.92% |
| 3. FCF Margin 8.34% |
| 4. Debt/Equity -24.54 |
| 5. Debt/Ebitda 4.47 |
| 6. ROIC - WACC (= 7.06)% |
| 7. RoE -5.10% |
| 8. Rev. Trend 95.75% |
| 9. EPS Trend -20.55% |
What is the price of AMRX shares?
Over the past week, the price has changed by +0.25%, over one month by +2.61%, over three months by +22.10% and over the past year by +54.17%.
Is AMRX a buy, sell or hold?
- Strong Buy: 1
- Buy: 3
- Hold: 0
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the AMRX price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 13.5 | 10.6% |
| Analysts Target Price | 13.5 | 10.6% |
| ValueRay Target Price | 17.5 | 43.6% |
AMRX Fundamental Data Overview December 06, 2025
P/E Trailing = 1194.0
P/E Forward = 6.2972
P/S = 1.2789
P/B = 86.1038
Beta = 1.38
Revenue TTM = 2.93b USD
EBIT TTM = 315.2m USD
EBITDA TTM = 555.6m USD
Long Term Debt = 2.57b USD (from longTermDebt, last quarter)
Short Term Debt = 21.5m USD (from shortTermDebt, last quarter)
Debt = 2.69b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 2.48b USD (from netDebt column, last quarter)
Enterprise Value = 6.24b USD (3.75b + Debt 2.69b - CCE 201.2m)
Interest Coverage Ratio = 1.28 (Ebit TTM 315.2m / Interest Expense TTM 246.5m)
FCF Yield = 3.92% (FCF TTM 244.8m / Enterprise Value 6.24b)
FCF Margin = 8.34% (FCF TTM 244.8m / Revenue TTM 2.93b)
Net Margin = 0.20% (Net Income TTM 5.90m / Revenue TTM 2.93b)
Gross Margin = 36.76% ((Revenue TTM 2.93b - Cost of Revenue TTM 1.86b) / Revenue TTM)
Gross Margin QoQ = 34.92% (prev 39.51%)
Tobins Q-Ratio = 1.73 (Enterprise Value 6.24b / Total Assets 3.60b)
Interest Expense / Debt = 2.34% (Interest Expense 62.8m / Debt 2.69b)
Taxrate = 447.2% (out of range, set to none) (-23.4m / -5.22m)
NOPAT = unknown (EBIT/Op.Income or Taxrate missing)
Current Ratio = 2.13 (Total Current Assets 1.84b / Total Current Liabilities 862.1m)
Debt / Equity = -24.54 (negative equity) (Debt 2.69b / totalStockholderEquity, last quarter -109.5m)
Debt / EBITDA = 4.47 (Net Debt 2.48b / EBITDA 555.6m)
Debt / FCF = 10.15 (Net Debt 2.48b / FCF TTM 244.8m)
Total Stockholder Equity = -115.7m (last 4 quarters mean from totalStockholderEquity)
RoA = 0.16% (Net Income 5.90m / Total Assets 3.60b)
RoE = -5.10% (negative equity) (Net Income TTM 5.90m / Total Stockholder Equity -115.7m)
RoCE = 12.86% (EBIT 315.2m / Capital Employed (Equity -115.7m + L.T.Debt 2.57b))
RoIC = 12.43% (EBIT 315.2m / (Assets 3.60b - Curr.Liab 862.1m - Cash 201.2m))
WACC = 5.36% (E(3.75b)/V(6.44b) * Re(9.20%) + (debt cost/tax rate unavailable))
Discount Rate = 9.20% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 15.44%
[DCF Debug] Terminal Value 77.77% ; FCFE base≈238.9m ; Y1≈294.7m ; Y5≈502.8m
Fair Price DCF = 22.00 (DCF Value 6.92b / Shares Outstanding 314.4m; 5y FCF grow 25.0% → 3.0% )
EPS Correlation: -20.55 | EPS CAGR: -1.51% | SUE: 0.49 | # QB: 0
Revenue Correlation: 95.75 | Revenue CAGR: 10.64% | SUE: 0.39 | # QB: 0
EPS next Quarter (2026-03-31): EPS=0.19 | Chg30d=+0.010 | Revisions Net=+1 | Analysts=3
EPS next Year (2026-12-31): EPS=0.94 | Chg30d=+0.038 | Revisions Net=+0 | Growth EPS=+17.9% | Growth Revenue=+6.7%
Additional Sources for AMRX Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle